Antibody Response and Neutrophil Mediation of  Chlamydia trachomatis infections

Team Members

Samantha D. Armijo

Andzoa N. Jamus

Zoe E. R. Wilton

Susan B. Core​

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for Chlamydia trachomatis vaccines. 

We identify antigens of interest that are important for Chlamydia trachomatis infection, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block Chlamydia trachomatis infection.

We also investigate how neutrophils respond in antibody mediated killing experiments to Chlamydia trachomatis infection.

Funding

NIH/NIAID R01AI166360, to Kathryn Frietze

NIH/NIAID U19AI113187, EPIC-STI NIAID Cooperative Research Center 

NIH/NIAID F30 Fellowship to Amanda L. Collar

NIH/NIAID T32 Pre-Doctoral Fellowship to Amanda L. Collar

NIH/NIAID T32 Pre-Doctoral Fellowship to Andzoa N. Jamus

University of New Mexico CTSC Pilot Award 2021 Kathryn M. Frietze